Your browser is no longer supported. Please, upgrade your browser.
Settings
DFFN Diffusion Pharmaceuticals Inc. daily Stock Chart
DFFN [NASD]
Diffusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own25.87% Shs Outstand15.18M Perf Week-12.06%
Market Cap26.57M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.40M Perf Month4.17%
Income-16.80M PEG- EPS next Q- Inst Own8.70% Short Float2.07% Perf Quarter-27.98%
Sales- P/S- EPS this Y31.30% Inst Trans255.34% Short Ratio1.34 Perf Half Y-40.88%
Book/sh0.11 P/B15.91 EPS next Y- ROA-62.90% Target Price89.30 Perf Year-80.34%
Cash/sh0.49 P/C3.59 EPS next 5Y- ROE- 52W Range1.34 - 15.50 Perf YTD-22.57%
Dividend- P/FCF- EPS past 5Y64.30% ROI- 52W High-88.71% Beta-0.42
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low30.61% ATR0.17
Employees10 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)43.56 Volatility10.74% 9.49%
OptionableNo Debt/Eq2.00 EPS Q/Q284.30% Profit Margin- Rel Volume0.17 Prev Close1.76
ShortableYes LT Debt/Eq0.00 EarningsAug 21 Payout- Avg Volume160.36K Price1.75
Recom- SMA20-1.80% SMA50-4.26% SMA200-38.56% Volume27,775 Change-0.57%
Sep-13-17 07:49PM  Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)? Simply Wall St. -5.03%
Sep-05-17 11:11AM  Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +6.18%
Aug-31-17 11:00AM  DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017 Zacks Small Cap Research
Aug-23-17 07:30AM  Diffusion Pharmaceuticals Names William Hornung Chief Business Officer GlobeNewswire
Aug-14-17 04:01PM  Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jul-31-17 08:30AM  Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer GlobeNewswire
Jul-21-17 08:00AM  Today's Research Reports on Trending Tickers: Diffusion Pharmaceuticals Inc. and Juno Therapeutics Inc. Accesswire
Jul-20-17 08:30AM  Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer GlobeNewswire +10.31%
Jul-06-17 08:00AM  Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors GlobeNewswire
May-26-17 10:00AM  Diffusion Pharmaceuticals to Present at the 7th Annual LD Micro Invitational Accesswire
May-25-17 12:00PM  DFFN: Focusing on Inoperable GBM Patients for Phase 3 Trial of TSC Zacks Small Cap Research
May-15-17 04:05PM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results GlobeNewswire
Apr-07-17 12:00PM  DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017 Zacks Small Cap Research -7.57%
Apr-04-17 08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications GlobeNewswire +12.01%
08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications
Apr-03-17 08:40AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E -10.28%
08:30AM  Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement GlobeNewswire
Mar-31-17 04:25PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement +10.83%
11:58AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
08:30AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results GlobeNewswire
Mar-29-17 09:30AM  Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First Accesswire -26.51%
Mar-15-17 09:10AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E
Feb-08-17 11:35AM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:35AM  Wednesdays Biggest Biopharma Movers
08:00AM  Diffusion Pharmaceuticals TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery GlobeNewswire
Jan-27-17 06:14AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-26-17 03:52PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, R -6.33%
Jan-12-17 09:30AM  Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments Accesswire -6.33%
Jan-10-17 10:42AM  This Small-Cap Rotation Is Unconvincing TheStreet.com +46.49%
10:42AM  This Small-Cap Rotation Is Unconvincing
Jan-09-17 04:34PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +176.70%
Dec-12-16 08:30AM  Diffusion Pharmaceuticals Files Definitive Proxy Statement for Upcoming Special Meeting of Stockholders GlobeNewswire
Nov-19-16 01:04PM  DIFFUSION PHARMACEUTICALS INC. Financials
Nov-14-16 11:30AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results GlobeNewswire
Nov-08-16 11:02AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Announces Uplisting to NASDAQ Capital Market GlobeNewswire
Oct-13-16 04:45PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Jun-08-16 06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Capital Cube
06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-31-16 11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer Zacks Small Cap Research
11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.